Renal cell carcinoma
Conditions
Interventions
Experimental group:Argon knife
Control group:conventional suture
Sponsors
Shanghai Ninth People's Hospital, Shanghai Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with T1 stage renal tumor, R.E.N.A.L score = 90g/L (no blood transfusion within 14 days); 2) ANC >= 1.5x10^9/L; 3) PLT >= 80x10^9/L; (2) The biochemical examination shall meet the following standards: 1) TBIL = 60ml/min; (3) Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) >= the lower limit of normal (50%). 5. Females of childbearing age should agree to use contraceptive measures (such as intrauterine devices, contraceptives or condoms) during the study period and within 12 months after the end of the study; negative serum or urine pregnancy test within 7 days before study enrollment , and must be a non-breastfeeding patient; 6. Agree to complete the inspections required by the project, including 4 radionuclide renal dynamic GFR within one year; 7. The patients voluntarily joined the study, signed the informed consent, and had good compliance.
Exclusion criteria
Exclusion criteria: 1. Patients with any severe and/or uncontrolled disease, including: (1) Patients with unsatisfactory blood pressure control (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg); suffering from myocardial ischemia or myocardial infarction above grade I, arrhythmia (including QT interval >= 440ms) and grade I cardiac function incomplete; (2) Active or uncontrolled serious infection; (3) Liver diseases such as cirrhosis, decompensated liver disease, chronic active hepatitis; (4) Poor control of diabetes (fasting blood glucose (FBG) > 10mmol/L); (5) When the urine routine indicates that the urine protein is >= ++, the urine protein quantification should be carried out, and the 24-hour urine protein quantification > 1.0 g should be confirmed. 2. Patients with bleeding tendency (such as active peptic ulcer) or who are receiving thrombolytic or anticoagulant therapy such as warfarin, heparin or their analogs; 3. Those who have experienced arterial/venous thrombotic events within 6 months, such as cerebrovascular accident (including temporary ischemic attack), deep vein thrombosis and pulmonary embolism; 4. Those with a history of psychotropic drug abuse and unable to quit or have a mental disorder; 5. A history of immunodeficiency, including HIV positive test or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation; 6. Patients with malignant tumors of other organ systems at the same time; 7. According to the judgment of the investigator, there are concomitant diseases that seriously endanger the patient's safety or affect the patient's completion of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| renal function;eGFR; | — |
Secondary
| Measure | Time frame |
|---|---|
| Warm ischemia time;Bleeding;surgery time; | — |
Countries
China
Contacts
Public ContactXu Bin
Shanghai Ninth People's Hospital, Shanghai Jiaotong University
Outcome results
None listed